Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical experience with cinacalcet HCl.

Pablo Ureña Torres1

  • 1Clinique de l'Orangerie, Service de Néphrologie-Dialyse, 11 boulevard Anatole France, 93300 Aubervilliers, France. urena.pablo@wanadoo.fr

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
|July 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathophysiology and therapies of CKD-associated secondary hyperparathyroidism.

Clinical kidney journal·2025
Same author

Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance.

Clinical kidney journal·2024
Same author

[Cardiovascular calcifications in dialysis patients].

Nephrologie & therapeutique·2023
Same author

Correction to: Independent effects of parathyroid hormone and phosphate levels on hard outcomes in non-dialysis patients: food for thought.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2022
Same author

Independent effects of parathyroid hormone and phosphate levels on hard outcomes in non-dialysis patients: food for thought.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2021
Same author

Worldwide Early Impact of COVID-19 on Dialysis Patients and Staff and Lessons Learned: A DOPPS Roundtable Discussion.

Kidney medicine·2021
Same journal

Evidence-Based Medicine versus Personalized Medicine when attempting to block complement in IgA nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Impact of immunosuppressive therapy on renal and patient survival in rapidly progressive secondary IgA nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Severe Pregnancy-Associated Acute Kidney Injury and Maternal Vulnerability.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Correction to: Hyponatraemia-treatment standard 2024.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same journal

Beyond Diffusion and Convection: Is Adsorption the Third Dimension of Dialysis?

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
See all related articles

Secondary hyperparathyroidism (SHPT) in dialysis patients can be effectively managed with cinacalcet HCl. This calcimimetic drug significantly reduces parathyroid hormone (PTH), phosphorus, and calcium-phosphorus product levels with good tolerability.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Secondary hyperparathyroidism (SHPT) is a common complication in end-stage renal disease (ESRD), leading to bone and mineral metabolism disturbances.
  • Current treatments like phosphate binders and vitamin D compounds have significant side effects, including hypercalcemia and hyperphosphatemia.

Purpose of the Study:

  • To evaluate the efficacy and safety of cinacalcet HCl, a novel calcimimetic agent, for treating SHPT in ESRD patients.

Main Methods:

  • Clinical trials involving dialysis patients with uncontrolled SHPT despite existing therapies.
  • Administration of cinacalcet HCl to assess its impact on parathyroid hormone (PTH), phosphorus, and calcium-phosphorus product (Ca x P) levels.

Main Results:

Related Experiment Videos

  • Cinacalcet HCl rapidly reduced plasma PTH, phosphorus, and Ca x P levels.
  • These reductions were sustained for up to 3 years in clinical trials.
  • The drug was generally well-tolerated, with transient nausea, vomiting, and hypocalcemia being the main reported side effects.

Conclusions:

  • Cinacalcet HCl represents a promising and well-tolerated therapeutic option for managing SHPT in patients with ESRD.
  • This calcimimetic agent offers an effective approach to controlling key mineral and hormonal imbalances associated with the condition.